Immune Cell Infiltrates and Neutrophil-to-Lymphocyte Ratio in Relation to Response to Chemotherapy and Prognosis in Laryngeal and Hypopharyngeal Squamous Cell Carcinomas.
PD-L1
chemotherapy
hypopharynx
larynx
neutrophil-to-lymphocyte ratio
squamous cell carcinoma
tumor infiltrating lymphocytes
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Apr 2021
25 Apr 2021
Historique:
received:
19
03
2021
revised:
20
04
2021
accepted:
23
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Our goal was to assess the correlation of immune parameters with the response to induction chemotherapy (ICT) in head and neck squamous cell carcinoma (HNSCC) patients. Pretreatment biopsies from 64 patients with HNSCC that received ICT were assessed for PD-L1 protein expression and density of CD8+ and FOXP3+ tumor infiltrating lymphocytes (TIL). In addition, the neutrophil-to-lymphocyte ratio (NLR) was calculated from pretreatment whole blood counts. In total, 55% of cases exhibited PD-L1 combined proportion score (CPS) positivity (≥1% stained cells). PD-L1 CPS positivity correlated with a high density of both CD8+ (
Identifiants
pubmed: 33923066
pii: cancers13092079
doi: 10.3390/cancers13092079
pmc: PMC8123315
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Instituto de Salud Carlos III
ID : PI16/00280
Organisme : Instituto de Salud Carlos III
ID : PI19/00560
Organisme : Instituto de Salud Carlos III
ID : PI19/00098
Organisme : Centro de Investigación Biomédica en Red de Cáncer
ID : CB16/12/00390
Organisme : Centro de Investigación Biomédica en Red de Cáncer
ID : CB16/12/00443
Organisme : Gobierno del Principado de Asturias
ID : IDI2018/155
Organisme : Merck Company Foundation
ID : 17-CC-008
Références
Sci Rep. 2020 Jan 27;10(1):1243
pubmed: 31988315
Medicine (Baltimore). 2017 May;96(18):e6369
pubmed: 28471952
Cancer Res. 2015 Jun 1;75(11):2139-45
pubmed: 25977340
J Clin Oncol. 2006 Feb 1;24(4):593-8
pubmed: 16380415
Cancer Immunol Immunother. 2012 Oct;61(10):1849-56
pubmed: 22456757
J Immunother Cancer. 2019 Jul 15;7(1):184
pubmed: 31307547
J Laryngol Otol. 2015 Nov;129(11):1046-52
pubmed: 26429303
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Cancer Immunol Immunother. 2020 Oct;69(10):2089-2100
pubmed: 32448984
Sci Rep. 2020 Aug 4;10(1):13078
pubmed: 32753659
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
J Cancer. 2018 Feb 12;9(5):861-871
pubmed: 29581764
Oncoimmunology. 2017 Aug 9;6(11):e1356148
pubmed: 29147608
Int J Cancer. 2017 Aug 1;141(3):594-603
pubmed: 28480996
Oral Oncol. 2014 Feb;50(2):128-34
pubmed: 24239278
Br J Cancer. 2011 Jun 28;105(1):93-103
pubmed: 21629244
Head Neck. 2020 Feb;42(2):336-343
pubmed: 31750591
J Cancer. 2019 Oct 22;10(26):6703-6710
pubmed: 31777599
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
Oncotarget. 2017 Oct 6;8(54):92699-92714
pubmed: 29190949
Laryngoscope. 2020 Apr;130(4):E144-E150
pubmed: 31006874
Head Neck. 2018 Mar;40(3):647-655
pubmed: 29076207
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
Cancer Immunol Res. 2015 Apr;3(4):326-32
pubmed: 25527356
Cancer Sci. 2018 Apr;109(4):966-979
pubmed: 29464828
ORL J Otorhinolaryngol Relat Spec. 2019;81(2-3):82-91
pubmed: 31112985
Cancer Immunol Immunother. 2020 May;69(5):689-702
pubmed: 32030476
BMC Cancer. 2015 Sep 04;15:617
pubmed: 26341881
Eur J Cancer. 2016 Jul;62:132-7
pubmed: 27189322
Am J Clin Pathol. 2016 Nov 1;146(5):546-553
pubmed: 27694130
Cancer Immunol Immunother. 2012 Aug;61(8):1155-67
pubmed: 22692756
Head Neck. 2018 May;40(5):1091-1100
pubmed: 29356179
Oncol Lett. 2018 Apr;15(4):4988-4996
pubmed: 29552135
Br J Cancer. 2014 Jan 21;110(2):501-9
pubmed: 24129245
Br J Cancer. 2019 May;120(10):1003-1006
pubmed: 30967647
Oral Oncol. 2018 Nov;86:81-90
pubmed: 30409325
J Clin Oncol. 2018 Apr 10;36(11):1143-1169
pubmed: 29172863
Oral Oncol. 2019 Apr;91:47-55
pubmed: 30926062
Oral Oncol. 2015 Mar;51(3):221-8
pubmed: 25500094
Oncotarget. 2017 Jul 6;8(46):80443-80452
pubmed: 29113315